to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction
Completed · Not applicable
Conditions studied: Meibomian Gland Dysfunction, Dry Eye Syndromes, Dry Eye
In brief
A Randomized, Masked (Evaluator), Controlled, Prospective Study Evaluating the Effectiveness and Safety of the Tixel® Medical Device, Versus LipiFlow® in the Treatment of Meibomian Gland Dysfunction
Key facts
- Study ID
- NCT05162261
- Run by
- Novoxel Ltd.
- People needed
- 109
- Starts
- 2022-09-19
- Expected to finish
- 2023-09-28
- Last updated by the study team
- 2025-01-22
Who can join
Age: 22 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Gordon Schanzlin New Vision Institute — La Jolla, California, United States
- Visionary Research Institute — Newport Beach, California, United States
- Moyes Eye Center — Kansas City, Missouri, United States
- Ophthalmology Associates — St Louis, Missouri, United States
- PNV Clinical Research, LLC — Texas City, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.